Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK5102188
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**GSK5102188** is an investigational adjuvanted recombinant subunit vaccine developed by GSK for the prevention of urinary tract infections (UTIs). It targets uropathogenic *Escherichia coli* (UPEC) antigens to stimulate immune responses against bacterial pathogens responsible for uncomplicated UTIs. Currently entering Phase I/II clinical trials, it represents GSK's effort to address unmet needs in preventive infectious disease vaccination.[3][2][1]
- Other names
- Urinary Tract Infection Vaccine
Beyond the preview
Go deeper on GSK5102188.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK5102188.